Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Appili Therapeutics Inc

Healthcare US APLIF

0.01USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0090.03
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap1.82M
  • Volume14000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.16005M
  • Revenue TTM0.21M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.21M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -2.60586M -3.71133M -9.20662M -25.07984M -14.32511M
Minority interest - - - - -
Net income -2.62469M -3.78091M -9.24301M -25.11830M -14.32511M
Selling general administrative 2.85M 3.05M 4.44M 5.27M 5.44M
Selling and marketing expenses - 0.14M - - -
Gross profit 0.10M 0.83M - - -
Reconciled depreciation 0.01M 0.01M 0.00627M 0.01M 0.01M
Ebit 0.35M -2.08032M - -24.62167M -15.65994M
Ebitda 0.36M -2.06666M -8.10427M -23.51226M -14.24044M
Depreciation and amortization 0.01M 0.01M - - -
Non operating income net other - - - - -
Operating income -0.19084M -2.16279M -7.77581M -23.55863M -14.37223M
Other operating expenses 0.29M 2.99M - - -
Interest expense 2.95M 1.63M 1.10M 1.55M 0.07M
Tax provision 0.02M 0.07M 0.04M 0.04M -
Interest income 0.00004M 0.02M 0.03M 0.03M 0.12M
Net interest income -3.50085M -1.61419M -1.06620M -1.52121M 0.05M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.07M - 0.04M -
Total revenue 0.10M 0.83M 0.33M 1.39M 0.00000M
Total operating expenses 0.29M 2.99M 8.11M 24.95M 14.37M
Cost of revenue - 0.01M - - -
Total other income expense net -2.41502M -1.54854M -0.36461M - -
Discontinued operations - - - - -
Net income from continuing ops -2.62469M -3.78091M -9.24301M -25.11830M -14.32511M
Net income applicable to common shares - - - -25.11830M -14.32511M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 3.03M 1.49M 3.13M 8.28M 18.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.11M 0.19M - - -
Total liab 16.43M 12.42M 10.53M 11.55M 5.56M
Total stockholder equity -13.39734M -10.92478M -7.39698M -3.27054M 12.75M
Deferred long term liab - - - - -
Other current liab - 0.08M - 0.12M -
Common stock 42.32M 42.32M - 39.65M 34.96M
Capital stock 42.32M 42.32M 42.32M 39.65M 34.96M
Retained earnings -71.71781M -69.09312M -65.31221M -56.06919M -30.95089M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - - -
Cash 1.23M 0.09M 2.47M 6.66M 11.06M
Cash and equivalents - - - - -
Total current liabilities 15.69M 11.54M 2.98M 6.67M 4.62M
Current deferred revenue - 0.05M - - -
Net debt 11.07M 8.09M 5.20M - -
Short term debt 11.56M 7.31M - - -
Short long term debt 11.56M 7.31M 0.11M 0.10M 0.09M
Short long term debt total 12.29M 8.18M - - -
Other stockholder equity 16.00M 15.84M - 8.13M 6.19M
Property plant equipment - - - 0.04M 0.05M
Total current assets 3.01M 1.46M 3.12M 8.24M 18.26M
Long term investments - - - - -
Net tangible assets - - - -3.27054M 12.75M
Short term investments - - - 0.00000M 5.06M
Net receivables 1.67M 1.17M - 1.39M 1.69M
Long term debt 0.74M 0.88M 7.55M 4.88M 0.95M
Inventory - - - - 0.00000M
Accounts payable 4.11M 4.11M 2.82M 6.38M 4.45M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.98M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.02M 0.03M 0.01M 0.04M 0.05M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.00236M -0.02906M -0.00317M 5.06M -4.98450M
Change to liabilities - - - 1.65M 2.70M
Total cashflows from investing activities -0.00236M -0.02906M - 5.06M -4.99295M
Net borrowings 0.26M 0.20M - 3.83M -0.01761M
Total cash from financing activities 0.19M 0.12M 5.91M 9.56M 17.02M
Change to operating activities - - - 0.27M -0.23306M
Net income -2.62469M -3.78091M -9.24301M -25.11830M -14.32511M
Change in cash 1.13M -2.37139M -4.19259M -4.39808M 0.55M
Begin period cash flow 0.09M 2.47M 6.66M 11.06M 10.51M
End period cash flow 1.23M 0.09M 2.47M 6.66M 11.06M
Total cash from operating activities 0.87M -2.46442M -10.09784M -19.08118M -11.45065M
Issuance of capital stock - 0.00000M 3.21M 5.34M 13.07M
Depreciation 0.01M 0.01M 0.00627M 0.01M 0.01M
Other cashflows from investing activities - 0.00065M - - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - - 0.00000M 0.04M
Change to account receivables -0.49754M -0.75255M 0.35M 0.57M -0.85982M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.06450M -0.08153M - 0.35M 2.47M
Change to netincome - - - 3.54M 1.22M
Capital expenditures 0.00236M 0.03M 0.00317M 0.00000M 0.00845M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.22619M -0.99938M -3.23559M 2.49M 1.64M
Stock based compensation 0.12M 0.19M 0.88M 2.04M 1.17M
Other non cash items 3.59M 2.11M 1.10M 1.55M 0.02M
Free cash flow 0.87M -2.49414M -10.10101M -19.08118M -11.45910M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APLIF
Appili Therapeutics Inc		 - -% 0.01 - 1.66 8.81 1.48 68.70 -2.7982
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Inc

1344 Summer Street, Halifax, NS, Canada, B3H 0A8

Key Executives

Name Title Year Born
Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., Pharmd CEO, Pres & Director NA
Mr. Kenneth G. Howling Acting Chief Financial Officer NA
Dr. Yoav Golan M.S., M.D., MS Chief Medical Officer 1962
Dr. Donald D. Cilla Jr., M.B.A., Pharmd CEO, President & Director NA
Mr. Kenneth G. Howling Chief Financial Officer NA
Dr. Gary S. Nabors Ph.D. Chief Development Officer NA
Dr. Carl Gelhaus Ph.D. Director of Non-Clinical Research NA
Mr. Arthur Baran Director of New Product Development NA
Jenna McNeil Corporate Affairs & Communications Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.